Advertisement
Screener

Coherus Oncology, Inc. (CHRS) Graph

CHRS Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue (m); Revenue including tax $14.31M; Cost of revenue $4.24M; Research and development $21.44M.
  • 2026-03-31: Revenue (m); Revenue including tax $12.31M; Cost of revenue $3.81M; Research and development $21.54M.
  • 2025-12-31: Revenue (m); Revenue including tax $12.75M*; Cost of revenue $4.04M*; Research and development $30.97M*.
  • 2025-09-30: Revenue (m); Revenue including tax $11.57M; Cost of revenue $3.72M; Research and development $27.25M.

Product or service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

CHRS revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Product AndService Other$694.00KToripalimab$13.61MRevenue$14.31MCost of revenue$4.24MOperating income-$32.33MOther income, net$1.31MResearch & development$21.44MSelling, general& administrative$20.95MPre-tax income-$33.35MNet income-$20.63M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueRevenue including taxCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30(m)$14.31M$4.24M$21.44M$20.95M(m)(m)-$20.63M
2026-03-31(m)$12.31M$3.81M$21.54M$23.10M(m)(m)-$38.33M
2025-12-31(m)$12.75M*$4.04M*$30.97M*$23.61M*(m)(m)-$37.64M*
2025-09-30(m)$11.57M$3.72M$27.25M$24.93M(m)(m)-$35.53M
2025-06-30(m)$10.25M$3.40M$26.31M$26.04M(m)(m)$297.77M
2025-03-31(m)$7.60M$2.65M$24.36M$26.02M(m)(m)-$56.57M
2024-09-30(m)$6.05M$2.73M$22.05M$28.13M(m)(m)-$10.75M
2024-06-30(m)$10.30M$1.81M$20.60M$27.52M(m)(m)-$12.92M
2024-03-31(m)$2.31M$1.44M$28.42M$40.23M(m)(m)$102.88M
2023-09-30(m)$74.57M$32.70M$25.65M$48.22M(m)-$380.00K-$39.64M
2023-06-30(m)$58.72M$24.85M$23.27M$45.14M(m)(m)-$42.87M
2023-03-31(m)$32.44M$16.87M$34.15M$49.15M(m)(m)-$75.73M
2022-09-30(m)$45.42M$35.23M$45.81M$44.83M(m)(m)-$86.65M
2022-06-30(m)$60.15M$11.28M$41.61M$51.28M(m)(m)-$50.15M
2022-03-31(m)$60.12M$9.37M$82.92M$48.75M(m)(m)-$96.08M
2021-09-30(m)$82.50M$21.28M$54.09M$39.92M(m)$0.00-$38.53M
2021-06-30(m)$87.64M$16.70M$54.77M$40.34M(m)$0.00-$29.90M
2021-03-31(m)$83.03M$7.51M$203.49M$39.39M(m)$0.00-$172.95M
2020-09-30(m)$113.55M$9.00M$38.85M$31.98M$79.83M$183.00K$27.93M
2020-06-30(m)$135.67M$10.14M$26.17M$34.05M$70.36M$1.29M$59.03M
2020-03-31(m)$116.18M$6.86M$33.11M$35.35M$75.31M$933.00K$35.57M
2019-12-31$123.86M(m)(m)(m)(m)$78.82M(m)(m)
2019-09-30$111.68M$111.68M(m)$21.57M$31.83M$59.84M$847.00K$47.04M
2019-06-30$83.43M$83.43M$601.00K$18.88M$36.46M$55.94M$51.00K$23.57M
2019-03-31$37.10M$37.10M$2.23M$18.79M$32.68M$53.70M$0.00-$20.00M
2018-12-31$0.00(m)(m)(m)(m)$60.50M(m)-$62.60M
2018-09-30$0.00$0.00(m)$31.60M$25.37M$56.97M$0.00-$58.81M
2018-06-30$0.00$0.00$0.00$26.52M$18.39M$44.91M$0.00-$43.64M
2018-03-31$0.00$0.00$0.00$25.45M$16.58M$42.03M(m)-$44.30M
2017-12-31$0.00(m)(m)(m)(m)$46.47M(m)-$49.07M
2017-09-30$0.00(m)(m)$42.63M(m)$56.62M(m)-$58.99M
2017-06-30$1.40M(m)(m)$34.50M(m)$58.03M(m)-$55.34M
2017-03-31$161.00K(m)(m)$53.77M(m)$72.58M(m)-$74.78M
2016-12-31$844.00K(m)(m)(m)(m)$74.30M(m)-$75.92M
2016-09-30$162.84M(m)(m)$64.57M(m)$78.22M(m)$83.94M
2016-06-30$14.07M(m)(m)$65.54M(m)$76.80M(m)-$69.97M
2016-03-31$12.36M(m)(m)$65.31M(m)$76.71M(m)-$65.39M
2015-12-31$10.20M(m)(m)(m)(m)$62.41M(m)-$52.39M
2015-09-30$7.17M(m)(m)$68.22M(m)$78.38M(m)-$71.33M
2015-06-30$6.87M(m)(m)$56.94M(m)$65.76M(m)-$58.81M
2015-03-31$5.81M(m)(m)$36.47M(m)$42.56M(m)-$40.73M
2014-12-31$6.49M(m)(m)(m)(m)$33.05M(m)-$29.13M
2014-09-30$16.05M(m)(m)$18.50M(m)$22.48M(m)-$7.87M
2014-06-30$4.96M(m)(m)$18.93M(m)$22.90M(m)-$24.96M
2014-03-31$3.60M(m)(m)$13.94M(m)$17.36M(m)-$25.17M
2013-12-31$1.23M(m)(m)(m)(m)$11.72M(m)-$14.59M
2013-09-30$506.00K(m)(m)$4.93M(m)$7.29M(m)-$21.47M
2013-06-30$507.00K(m)(m)(m)(m)$9.79M(m)-$8.71M
2013-03-31$506.00K(m)(m)(m)(m)$9.95M(m)-$8.86M

Revenue and expense 6 month

Period endRevenueRevenue including taxCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30(m)$26.62M$8.06M$42.98M$44.06M(m)(m)-$58.96M
2025-06-30(m)$17.85M$6.05M$50.66M$52.06M(m)(m)$241.20M
2024-06-30(m)$12.60M$3.25M$49.02M$67.75M(m)(m)$89.95M
2023-06-30(m)$91.15M$41.72M$57.42M$94.30M(m)(m)-$118.60M
2022-06-30(m)$120.27M$20.65M$124.53M$100.03M(m)(m)-$146.23M
2021-06-30(m)$170.68M$24.21M$258.26M$79.74M(m)$0.00-$202.85M
2020-06-30(m)$251.85M$16.99M$59.28M$69.40M$145.68M$2.23M$94.60M
2019-06-30(m)$120.53M$2.83M$37.67M$69.14M$109.64M$51.00K$3.56M
2018-06-30(m)$0.00$0.00$51.97M$34.97M$86.94M$0.00-$87.94M
2017-06-30$1.56M(m)(m)$88.28M(m)$130.61M(m)-$130.11M
2016-06-30$26.43M(m)(m)$130.86M(m)$153.51M(m)-$135.35M
2015-06-30$12.68M(m)(m)$93.41M(m)$108.32M(m)-$99.53M
2014-06-30(m)(m)(m)$32.86M(m)$40.26M(m)-$50.13M

Revenue and expense 9 month

Period endRevenueRevenue including taxCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2025-09-30(m)$29.42M$9.77M$77.91M$77.00M(m)(m)$205.67M
2024-09-30(m)$18.66M$5.98M$71.07M$95.87M(m)(m)$79.20M
2023-09-30(m)$165.72M$74.42M$83.07M$142.52M(m)-$380.00K-$158.24M
2022-09-30(m)$165.69M$55.88M$170.34M$144.86M(m)(m)-$232.88M
2021-09-30(m)$253.18M$45.49M$312.34M$119.66M(m)$0.00-$241.38M
2020-09-30(m)$365.40M$25.99M$98.13M$101.39M$225.51M$2.41M$122.54M
2019-09-30(m)$232.22M(m)$59.24M$100.97M$169.48M$898.00K$50.61M
2018-09-30(m)$0.00(m)$83.58M$60.34M$143.91M$0.00-$146.74M
2017-09-30$1.56M(m)(m)$130.90M(m)$187.23M(m)-$189.10M
2016-09-30$189.26M(m)(m)$195.43M(m)$231.73M(m)-$51.42M
2015-09-30(m)(m)(m)$161.63M(m)$186.70M(m)-$170.87M
2014-09-30(m)(m)(m)$51.36M(m)$62.73M(m)-$58.00M
2013-09-30(m)(m)(m)$22.06M(m)$27.02M(m)-$39.04M

Revenue and expense 12 month

Period endRevenueRevenue including taxCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2025-12-31(m)$42.17M$13.81M$108.89M$100.60M(m)$0.00$168.02M
2024-12-31(m)$26.39M$8.73M$91.83M$125.48M(m)$0.00$28.51M
2023-12-31(m)$1.22M$438.00K$96.11M$120.46M(m)-$380.00K-$237.89M
2022-12-31(m)$211.04M$70.08M$199.36M$198.48M(m)$0.00-$291.75M
2021-12-31(m)$326.55M$57.59M$363.11M$169.71M(m)$0.00-$287.10M
2020-12-31(m)$475.82M$37.67M$142.76M$139.08M(m)$3.46M$132.24M
2019-12-31(m)$356.07M$17.08M$94.19M$137.04M$248.30M$2.94M$89.83M
2018-12-31$0.00$0.00(m)$110.24M$94.18M$204.42M$0.00-$209.34M
2017-12-31$1.56M$1.56M(m)$162.39M$71.30M$233.69M$0.00-$238.17M
2016-12-31(m)$189.48M(m)$254.44M$51.60M$306.04M$0.00-$127.34M
2015-12-31$30.04M(m)(m)$213.06M(m)$249.11M$0.00-$223.26M
2014-12-31$31.11M(m)(m)$78.22M(m)$95.79M$0.00-$87.13M
2013-12-31$2.75M(m)(m)$31.28M(m)$38.74M(m)-$53.63M
2012-12-31$1.90M(m)(m)$34.89M(m)$40.42M(m)-$33.02M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Alpha Cognition Inc. (ACOG)$0.185B-6.77
PRECISION BIOSCIENCES INC (DTIL)United States$0.175B-3.95
Voyager Therapeutics, Inc. (VYGR)United States$0.173B-1.99
Protara Therapeutics, Inc. (TARA)United States$0.198B-3.22
Acumen Pharmaceuticals, Inc. (ABOS)United States$0.162B-1.83
Outlook Therapeutics, Inc. (OTLK)United States$0.162B-4.90
Compass Therapeutics, Inc. (CMPX)United States$0.204B-5.35
Humacyte, Inc. (HUMA)United States$0.155B-2.26
Alector, Inc. (ALEC)United States$0.213B-1.90
ANAVEX LIFE SCIENCES CORP. (AVXL)United States$0.218B-18.37